Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRD3874-SI in Relapsed and Refractory Acute Myeloid Leukemia
NCT07661095Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of CRD3874 in acute myeloid leukemia (AML) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Jun 2026; status: recruiting.
02
Drugs
CRD3874
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07661095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07661095.